Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Belgium,Czech Republic,Germany,France,Switzerland,Australia,United States,United Kingdom,Spain,Canada
nct
Update Il y a 5 ans
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Netherlands
,
Serbia
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Lebanon
,
Lithuania
,
Netherlands
,
Russian Federation
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
Country
Australia
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
Country
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
Czech Republic
,
Denmark
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Japan
,
Mexico
,
Poland
,
Portugal
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
China
,
Czech Republic
,
France
,
Germany
,
Italy
,
Netherlands
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Atacicept in Subjects With Optic Neuritis
This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.
Country
Australia
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Lebanon
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Country
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1